Refine by
Microvessels Articles & Analysis: Older
17 news found
Systemic sclerosis (also known as scleroderma) is a chronic, autoimmune disease that leads to serious damage to the microvessels. Already in the first stages of the disease, patients are affected by episodes of reduced blood flow in fingers and toes. ...
Miracor Medical SA (Miracor Medical) today announced the first patient enrolled in the PICSO-AMI-V study to evaluate the benefits of PiCSO® (Pressure-controlled intermittent Coronary Sinus Occlusion) therapy as an adjunct to conventional primary percutaneous coronary intervention (PCI) for patients presenting with inferior ST-Elevation Myocardial Infarction (STEMI). The first patient ...
We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects who have not been diagnosed with DPN. By analyzing ...
Sonavex scored FDA clearance for its technology that uses ultrasound imaging and deep learning to deliver blood flow data on demand. The EchoSure system is cleared for use with the company’s EchoMark bioresorbable tissue markers, which got the agency’s nod in June. “The key goal is to be able to detect the problems associated with microvascular and vascular surgeries with ...
Coordinating Investigator Professor Ariane Herrick, The University of Manchester Centre for Musculoskeletal Research commented: "Systemic sclerosis is a chronic, autoimmune disease that leads to serious damage to the microvessels and which is associated with great unmet need. In the first stage, attacks of Raynaud's phenomenon occur, often followed by painful and ...
About Gesynta Pharma AB Gesynta Pharma's most advanced drug candidate GS-248 reduces inflammation and increases blood flow in the microvessels, which may provide improved treatments for several serious diseases. ...
Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the MagicTouch SCB Sirolimus Coated Balloon Catheter, for the treatment of small coronary artery lesions in Coronary Artery Disease (CAD). The proposed indication for use includes “The ...
Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients. The new system features improvements in ease of use. PiCSO therapy is delivered by interventional cardiologists during the primary PCI (Percutaneous Coronary Intervention) ...
Miracor Medical SA announces today that an update about PiCSO therapy will be presented during the upcoming PCR e-Course which will be held on June 25, 26 and 27. PiCSO therapy (Pressure-Controlled Intermittent Coronary Sinus Occlusion) is delivered by interventional cardiologists during the primary PCI (Percutaneous Coronary Intervention) procedure in patients experiencing anterior ST-elevated ...
Gesynta Pharma AB ("Gesynta"), a clinical stage company developing novel anti-inflammatory agents, today announced that the results from the successfully completed First-in-Human clinical study with its lead candidate GS-248 for the treatment of microvascular disease have been presented at the EULAR 2020 E-Congress. Following these results, Gesynta now intends to commence a Phase II study in ...
Gesynta Pharma AB ("Gesynta") announces the completion and positive results of a first clinical study with GS-248. The purpose of the study was to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties of GS-248 after single and multiple ascending doses to healthy subjects. The results support the further clinical development of GS-248 in microvascular dysfunction and a ...
Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced research findings that suggest the company’s Lumee® Oxygen Platform may help improve the clinical management of patients with critical limb ischemia (CLI) who are undergoing endovascular revascularization treatment (EVT). The data, from a recent post-market clinical study ...
Miracor Medical SA (Miracor Medical) today announced the initiation and first patient enrollment in the PICSO-AMI-I study to evaluate the benefits of PiCSO® therapy compared with conventional PCI for the treatment of anterior STEMI patients. The first patient enrolled into this study was treated at Oxford Heart Center, Oxford, UK by Professor Adrian Banning, the principal investigator of the ...
Gesynta Pharma AB ("Gesynta") announces that the first clinical study with GS-248 has been initiated and that the first healthy volunteers have been dosed. The purpose of the phase I study is to study safety, tolerability and pharmacokinetic properties of GS-248 as well as its effect on relevant biomarkers. Gesynta's lead candidate drug, GS-248, is a potent and selective inhibitor of ...
Sonavex, Inc., a privately held medical device company focused on empowered patient care, announced today that on March 8, 2019 it received 510(k) clearance from the U.S. Food and Drug Administration for its EchoSureTM device to deliver definitive blood flow data on demand. The EchoSure system combines 3D ultrasound imaging with advanced deep learning algorithms to automate visual and ...
Miracor Medical SA (Miracor Medical) today announced the final closing of the Series D financing round of €30M. The Series D capital will be used to further develop and commercialize the PiCSO® Impulse System. The Series-D round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor. Participating new investors include Belgian alternative investment fund Quest for ...
Miracor Medical SA today announced that new clinical data of the PiCSO® Impulse System for the treatment of STEMI patients will be presented during the EuroPCR conference in Paris, May 21st - 24th 2018. The PiCSO clinical results will be presented during two different sessions, including a Hotline session: Thursday May 24th @ 11:03 in the "Hotline Coronary Intervention" session, Room ...